NVAX · Novavax Inc
$10.46
-0.14 (-1.32%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$1.75B
Shares
164.95M
Volume · Oct 2
4.03M
Avg daily vol (3M)
4.45M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.46
Open$10.80
Day$10.33–10.86
52W close$6.22–11.19
Avg vol 30d5.6M
Short int49.9M · 30.2% float · 9.3d
Short vol57%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
call held May 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$413.80M
Trailing 12 months
Net income (TTM)
−$247.73M
Trailing 12 months
Revenue growth YoY
-76.3%
Year over year
Operating margin
-56.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-7.1%
Year over year · fewer shares
Price change (1Y)
+9.5%
Trailing year
Short interest
30.2%
Latest settlement · 9.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+18%
above
Price vs 50-day avg
+15%
above
RSI (14)
59
neutral
MACD trend
Negative
52-week position
85%
near high
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+29%
trailing
YTD return
+56%
this year
Relative strength
+17%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $9 — 50d above 200d
Institutional flow
Distributing
1 of 271 funds reported for Sep 30 · net -11 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
30.24% of float · ▲ +2.2% MoM · 9.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
271 holders — near 3-yr high, broad support
Squeeze score
88
high risk · 0–100
Fundamentals
Revenue growth
+65%
Y/Y
EPS growth
+310%
Y/Y
Balance sheet
$3.6M
net debt
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−35%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Combined R&D and SG&A Expenses
· Full Year 2026
Initiated
$380M – $420M
Non-GAAP Combined R&D and SG&A Expenses
· Full Year 2026
Initiated
$310M – $340M
Adjusted Total Revenue
· Full Year 2026
Initiated
$230M – $270M
Nuvaxovid Product Sales
· Full Year 2026
Initiated
$35M – $45M
Adjusted Supply Sales
· Full Year 2026
Initiated
$40M – $50M
Adjusted Licensing, Royalties and Other Revenue
· Full Year 2026
Initiated
$155M – $175M
Guided vs delivered
· last 3 settled
Total Revenue
Full Year 2024
guided $800M – $1B
$682.16M
Miss −24.2%
Total Revenue
First Quarter 2024
guided $100M
$93.86M
Miss −6.1%
Total Revenue
FY 2023
guided $900M – $1.1B
$983.71M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+18%
Bullish
Price vs 50-day avg
+15%
Bullish
RSI (14)
59
Neutral
MACD trend
Negative
Bearish
52-week position
85%
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $9 — 50d above 200d
Institutional flow
Distributing
1 of 271 funds reported for Sep 30 · net -11 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
30.24% of float · ▲ +2.2% MoM · 9.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
271 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $10 · 85%
Range high $11
vs 200-day avg +18%
vs 50-day avg +15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP Combined R&D and SG&A Expenses non-GAAP | $171.3M | Six Months Ended June 30, 2026 | — |
| Non-GAAP R&D Expenses non-GAAP | $115.9M | Six Months Ended June 30, 2026 | — |
| Non-GAAP R&D expenses, net of partner reimbursement non-GAAP | $48M | Q2 2026 | — |
| R&D expenses reimbursed by partners | $23M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NVAX
this stock
Novavax Inc
|
$1.75B | +55.7% | +64.7% | — | 30.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NVAX | -1.6% | +1.2% | +29.0% | -3.2% | +55.7% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -1.4% | +1.6% | +16.8% | -4.2% | +42.8% |